Takeda Pharmaceutical TKPHF

Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company engaged in the research, development, production, and global commercialization of pharmaceutical products. The company focuses on delivering innovative, life-transforming medicines by advancing treatment options for high unmet medical needs in both rare and prevalent conditions. Takeda operates in approximately 80 countries and regions with major research centers in Japan and the United States, and a significant commercial presence in the United States, Japan, Europe, and a growing business in China.

Takeda generates revenue primarily through the sale of its pharmaceutical products across six key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience. Revenue is derived from the commercialization of branded prescription drugs such as ENTYVIO for inflammatory bowel disease, TAKHZYRO for hereditary angioedema, GAMMAGARD LIQUID/KIOVIG for immunodeficiency disorders, ALUNBRIG for non-small cell lung cancer, VYVANSE/ELVANSE for attention deficit hyperactivity disorder, and QDENGA for dengue prevention. The company serves patients, healthcare providers, and health systems worldwide through its global sales and marketing infrastructure.

The company operates through the following segments: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience.

• Gastroenterology focuses on the research, development, and commercialization of treatments for gastrointestinal diseases such as ulcerative colitis, Crohn’s disease, eosinophilic esophagitis, and short bowel syndrome, with key products including ENTYVIO, EOHILIA, TAKECAB/VOCINTI, and GATTEX/REVESTIVE.

• Rare Diseases encompasses therapies for hereditary angioedema, post-transplant cytomegalovirus infection, congenital thrombotic thrombocytopenic purpura, Hunter syndrome, Fabry disease, and hemophilia A, with principal products such as TAKHZYRO, LIVTENCITY, ADZYNMA, ELAPRASE, REPLAGAL, ADVATE, and ADYNOVATE/ADYNOVI.

• Plasma-Derived Therapies involves the collection, manufacturing, and commercialization of immunoglobulin and albumin products derived from human plasma, including GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, FLEXBUMIN, and Human Albumin, used to treat immunodeficiency disorders, neurological conditions, and volume depletion.

• Oncology develops and markets treatments for hematologic malignancies, solid tumors, and hormone-responsive cancers, featuring products like ALUNBRIG, FRUZAQLA, LEUPLIN/ENANTONE, NINLARO, ADCETRIS, and ICLUSIG for conditions including non-small cell lung cancer, metastatic colorectal cancer, prostate and breast cancer, multiple myeloma, Hodgkin lymphoma, and chronic myeloid leukemia.

• Vaccines focuses on the prevention of infectious diseases through vaccine development, with QDENGA as its principal product designed to protect against dengue fever in individuals aged four and older.

• Neuroscience develops treatments for neurological and psychiatric disorders such as attention deficit hyperactivity disorder, binge eating disorder, and major depressive disorder, with key products including VYVANSE/ELVANSE and TRINTELLIX.

Takeda holds a leading position in several therapeutic areas, particularly in gastroenterology with ENTYVIO as a top-selling product globally, and in rare diseases with TAKHZYRO and immunoglobulin therapies. The company competes with large biopharmaceutical firms such as Pfizer, Merck, Roche, AbbVie, and Bristol-Myers Squibb, as well as specialty players in niche markets. Its competitive advantages stem from a diversified portfolio, strong R&D pipeline, global manufacturing and plasma collection network, and strategic partnerships that enhance innovation and market reach.

Takeda serves a diverse customer base including hospitals, clinics, physicians, patients, and healthcare systems across the globe. The company’s products are used in outpatient and inpatient settings for chronic and acute conditions, with specific therapies administered in specialty care centers, infusion clinics, and retail pharmacies depending on the formulation and indication.